
《 》

"Smoking Cessation, Training Programme"

"Pharmacia & Upjohn Consumer Healthcare"

《》

.....

.....

.....

.....

.....

.....

.....


- - - - -

- - - - -

()

()

()



\

()

:

-

-

-

-

-

-

(%)

()

(%)

●

●

%


●

●

—

()

()



•
•
•
•

()

()

:

()

()

()

()

)

().(

:

•

•

•

•

: _____

: (

: (

: (

) : (

() : (

() : (

: (



()

()

()

()

:

•

•

•

•

()

:

•

•

•

•

•

:

/


()

(, , ,)

(, , ,)

)

(



:

/

●

●

●

()

•
•
•

%

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

() NRT

NRT

References:

- 1- Smoking kills, A White Paper on Tobacco. 1998.
- 2- Thomas M Walker et al. Office for national statistics. Living in Britain: results from the 1996 General Household Survey. London: The Stationery Office, 1998.
- 3- Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. *Annu Rev Pharmacol Toxicol* 1996;3: 597-613.
- 4- Royal College of Physicians of London. Nicotine addiction in Britain: a report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians, 2000.
- 5- Action on smoking and pregnancy. Health Education Authority. 1999.
- 6- Henningfield JE. Pathophysiology of nicotine dependence. In: Proceedings of the Smoking Cessation Consensus Meeting, March 1992, Thundridge.

:

+ = :

)

() (

•


•

•

%

%

%



:


●

●

:

()

:



•
•
•
•

ACTH

•
•
•
•

•

(Fagerstrom Tolerance Questionnaire; FTQ)

:

)

(

:

()

()

()

()

() ()

()

()

()

()

()

()

() ()

() ()

(DSM-IV)

•

•

•

:

()

() -

() -

:

•

•

•

()

•

()
()

References:

- 1- Fowler G. Smoking: time to confront a major health issue.
Update supplement May 2000.

:

() NRT -
NRT -NRT -
NRT -

:

NRT -
NRT -

(NRT)

	(NRT)
	()
	()
	()
	()

NRT •

NRT

(Ove Ferno)

(Pharmacia & Upjohn)

pH

NRT


NRT

pH

/

(NRT)

) .
)
(
(



: (NRT)

NRT

(double – blind)

(Raw) (Jarvis)

(Feyeraband) (Russell)

(NRT)

(OTC)

(OTC)

()

: **NRT**

CEASE

(ERS)

NRT

NRT

NRT

NRT

()

NRT

: NRT

NRT


NRT

()

NRT

() OTC

NRT



NRT

NRT . NRT :

.....

.....

.....

.....

.....

.....

.....

.....

.....

)
(
NRT

.....

α_2

•
•
•
•

()


•

•


•

•

NRT



« »



•

•

•

(Assist) (Advice) (Ask) : A

.(Arrange)

:

NRT

- - - - -

;

●

●

●

●

;

;

;

;

;

;

;

;

;

NRT

()

NRT

•
•
•

NRT

:

NRT

NRT

NRT

:

()

pH

NRT

()

References:

- 1- Fagerstrom KO, Sawe U. The pathophysiology of nicotine dependence: treatment options and the cardiovascular safety of nicotine. 1996;6(3):125-143
- 2- Fowler G. Smoking: time to confront a major health issue. Update supplement May 2000.
- 3- Thorax. The journal of the British Thoracic Society. Smoking Cessation Guidelines and their cost Effectiveness. December 1998. Vol 53. Supplement 5.



:

•

•

•

•

: _____

)

()

()

(%)

(%)

()

()

%

%

%


%


()

:

•

•





:

NRT

()

()			
	()		
	()		
	()		
	()		Tscopp

•
•



		()
--	--	-----

•

•

•

NRT

:

•

•

•

NRT

)

.

.(

)

.(

NRT


NRT

)

(

NRT

NRT	
NRT	



)

(

.

(

(

(

References:

- 1- Herrera N et al. Nicotine gum, 2mg and 4mg, for nicotine dependence: A double-blind placebo-controlled trial with in a behaviour modification support program. Chest 1995; 108:447-451.
- 2- Tang JL et al. BMJ 1994; 308: 21-6.
- 3- Blondal T. Controlled trail of nicotine polacrilex gum with supportive measures. Archives of Internal Medicine 149: 1818-1821, 1989.
- 4- Benowitz et al. Clinical Pharmacology and Therapeutics 41: 467-473, 1987.
- 5- Jarvis MJ et al. Randomised controlled trial of nicotine chewing gum. BMJ 285:537-540, 1982.
- 6- Data on file, Pharmacia.
- 7- Murray RP et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Chest 1996; 49: 438-445.



)

(

)

(


()

NRT


(P=0.017)

()

() ()



() (P<0.01)



(placebo)

:

:

()

()


.(())

()

(n =)	(n =)	(n =)	
% / % %	% / % %	% / % %	(/) P>0.05

().

:



:

•

:

•

:




•

:

NRT

)

(



•

• () •

•

NRT

.()
. ()

NRT

NRT

:

•

)

(

•

•

:

:

()

()

()

⋮

⋮

References:

- 1- Tonnesen P *et al.* A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. *N Engl J MEd.* 1991; 325: 311-15.
- 2- Stapleton JA *et al.* Dose effects and predictors of outcome in a randomised trial of nicotine patches in general practice. *Addiction.* 1995; 106: 421-7.
- 3- Fagerstrom KO, Sawe U. The pathophysiology of nicotine dependence: treatment options and the cardiovascular safety of nicotine. 1996; 6(3): 125-143.
- 4- Fagerstrom KO, Sachs DPL. Medical management of tobacco dependence: a critical review of nicotine skin patches. *Curr Pulmonology.* 1995; 16: 223-38.
- 5- Daughton *et al.* Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. *Archives of Internal Medicine.* 151: 749-752, 1991.

) NRT (

) () (




NRT

•

•

•

•



:

()

:

(P<0.05)

•

•

(cartridge)

)

.(



)

.

1

1

1



•

•

NRT

()
)
(

NRT

NRT

NRT

•

•

()

•

NRT

:

:

- - - - -

NRT

NRT

NRT

()

References:

- 1- Tonnesen P, Norregaard J, Mikkelsen K, *et al.* A double-blind trial of a nicotine Inhalator for smoking cessation. JAMA 1993; 269: 1268-71.
- 2- Schneider *et al.* Efficacy of a nicotine Inhalator in smoking cessation: a double- blind, placebo-controlled trial. Addiction 1996; 91(9), 1293-1306.


-
-
-
-
-
-
-
-

-
-
-
-
-
-

()

pH





:

•

)

•

.(

•

•

•

:



(open randomized cross-over)

()


(two-way cross-over)

()


()

.)

()



()



:

●

●

: _____

()

•

•

NRT

.

.

.

•

•

•

•

•


)

(

•

•

:



NRT

•

•

NRT

()

NRT

NRT

NRT

-

)

(

-

⋮

⋮

References:

- 1- Nicorette Sublingual Tablet Monograph. Data on file. Pharmacia.
- 2- Molander L, Lunell E, Fagerstrom KO. Reduction of tobacco withdrawal symptoms with a sublingual nicotine tablet: a placebo-controlled study. Nicotine & Tobacco Research (2000) 2: 187-191.
- 3- Wallstrom M, Nilsson F, Hirsch JM. A randomized double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. Addiction (2000) 95 (8).
- 4- Fagerstrom KO. Tejding R, Westin A, Lunell E. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker. Tobacco Control (1997) 6: 311-316.

(NRT)

(/)



:

●

●

(NRT)

●



●

:

()

()

()




)


(

().

(NRT)

()





% % % %
% () .
:

() .


•

•

•

•





:

•

•

•

:

()

(NRT)

= :

:

•

•

•

() •

(NRT)

.()
. ()

(NRT)

(NRT)

:

●

)

(

●

(NRT)

:

/

()

References:

- 1- Johansson CJ et al. Absolute bioavailability of nicotine applied to different nasal regions. European Journal of Clinical Pharmacology 1991; 41: 585-588.
- 2- Royal College of Physicians of London. Nicotine addiction in Britain: a report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians, 2000.
- 3- Sutherland et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324-328.
- 4- Meta-analysis. Sutherland et al. (1992), Schneider et al. (1992), Hjalmarson (1992).